Онкология FOUR ASPECTS OF ADJUVANT TARGETED THERAPY HER2 POSITIVE BREAST CANCER
eng
ONCOLOGY BULLETIN OF THE VOLGA REGION

Scientific-practical Journal for general practitioners and researchers

Search

FOUR ASPECTS OF ADJUVANT TARGETED THERAPY HER2 POSITIVE BREAST CANCER

V.F. Semiglazov1, V.V. Semiglazov2

1 Petrov Research Institute of Oncology, St. Petersburg
2 St. Petersburg State Medical University named after acad. I.P. Pavlov, St. Petersburg

 

Semiglazov V.V. — D. Med. Sc., Associate Professor, Head of the Department of Oncology of SPSMU
68 Leningradskaya St., township Pesochnyy-2, St. Petersburg, Russian Federation, 197758, tel.: (812) 596-87-57, 947-72-70, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.

 

Abstract. Several phase III clinical trials have studied the effect of trastuzumab in combination with chemotherapy on recurrence-free survival in patients with HER2-positive breast cancer, depending on the type of chemotherapy, duration of trastuzumab treatment and time of the its addition to the chemotherapy. All the major clinical studies have demonstrated the continued benefit of the one-year treatment with trastuzumab in addition to standard anthracycline/taxane-based chemotherapy.

Key words: breast cancer, HER2, adjuvant therapy, trastuzumab, chemotherapy.

 





Наши партнеры



Copyright © 2014 | Все права защищены
RAFANDOS.COM | SUPPORT